BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28775147)

  • 1. Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells.
    Fuse MA; Plati SK; Burns SS; Dinh CT; Bracho O; Yan D; Mittal R; Shen R; Soulakova JN; Copik AJ; Liu XZ; Telischi FF; Chang LS; Franco MC; Fernandez-Valle C
    Mol Cancer Ther; 2017 Nov; 16(11):2387-2398. PubMed ID: 28775147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.
    Petrilli AM; Garcia J; Bott M; Klingeman Plati S; Dinh CT; Bracho OR; Yan D; Zou B; Mittal R; Telischi FF; Liu XZ; Chang LS; Welling DB; Copik AJ; Fernández-Valle C
    Oncotarget; 2017 May; 8(19):31666-31681. PubMed ID: 28427224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cotargeting Phosphoinositide 3-Kinase and Focal Adhesion Kinase Pathways Inhibits Proliferation of NF2 Schwannoma Cells.
    Hardin HM; Dinh CT; Huegel J; Petrilli AM; Bracho O; Allaf AM; Karajannis MA; Griswold AJ; Ivan ME; Morcos J; Gultekin SH; Telischi FF; Liu XZ; Fernandez-Valle C
    Mol Cancer Ther; 2023 Nov; 22(11):1280-1289. PubMed ID: 37527526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas.
    Gehlhausen JR; Hawley E; Wahle BM; He Y; Edwards D; Rhodes SD; Lajiness JD; Staser K; Chen S; Yang X; Yuan J; Li X; Jiang L; Smith A; Bessler W; Sandusky G; Stemmer-Rachamimov A; Stuhlmiller TJ; Angus SP; Johnson GL; Nalepa G; Yates CW; Wade Clapp D; Park SJ
    Hum Mol Genet; 2019 Feb; 28(4):572-583. PubMed ID: 30335132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development.
    Fuse MA; Dinh CT; Vitte J; Kirkpatrick J; Mindos T; Plati SK; Young JI; Huang J; Carlstedt A; Franco MC; Brnjos K; Nagamoto J; Petrilli AM; Copik AJ; Soulakova JN; Bracho O; Yan D; Mittal R; Shen R; Telischi FF; Morrison H; Giovannini M; Liu XZ; Chang LS; Fernandez-Valle C
    Neuro Oncol; 2019 Mar; 21(4):486-497. PubMed ID: 30615146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2.
    Petrilli A; Copik A; Posadas M; Chang LS; Welling DB; Giovannini M; Fernández-Valle C
    Oncogene; 2014 Jul; 33(27):3571-82. PubMed ID: 23934191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of SIRT2 in merlin/NF2-mutant Schwann cells triggers necrosis.
    Petrilli A; Bott M; Fernández-Valle C
    Oncotarget; 2013 Dec; 4(12):2354-65. PubMed ID: 24259290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis.
    Nagel A; Huegel J; Petrilli A; Rosario R; Victoria B; Hardin HM; Fernandez-Valle C
    Oncogene; 2024 Mar; 43(13):921-930. PubMed ID: 38336988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis.
    Schulze KM; Hanemann CO; Müller HW; Hanenberg H
    Hum Mol Genet; 2002 Jan; 11(1):69-76. PubMed ID: 11773000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
    James MF; Han S; Polizzano C; Plotkin SR; Manning BD; Stemmer-Rachamimov AO; Gusella JF; Ramesh V
    Mol Cell Biol; 2009 Aug; 29(15):4250-61. PubMed ID: 19451225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1.
    Troutman S; Moleirinho S; Kota S; Nettles K; Fallahi M; Johnson GL; Kissil JL
    Oncotarget; 2016 Aug; 7(34):54515-54525. PubMed ID: 27363027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular mechanisms of heterogeneity in NF2-mutant schwannoma.
    Chiasson-MacKenzie C; Vitte J; Liu CH; Wright EA; Flynn EA; Stott SL; Giovannini M; McClatchey AI
    Nat Commun; 2023 Mar; 14(1):1559. PubMed ID: 36944680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
    Nam HJ; Im SA; Oh DY; Elvin P; Kim HP; Yoon YK; Min A; Song SH; Han SW; Kim TY; Bang YJ
    Mol Cancer Ther; 2013 Jan; 12(1):16-26. PubMed ID: 23144237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation and Use of Merlin-Deficient Human Schwann Cells for a High-Throughput Chemical Genomics Screening Assay.
    Petrilli AM; Fernández-Valle C
    Methods Mol Biol; 2018; 1739():161-173. PubMed ID: 29546707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.
    Stepanova DS; Semenova G; Kuo YM; Andrews AJ; Ammoun S; Hanemann CO; Chernoff J
    Cancer Res; 2017 Sep; 77(18):5026-5038. PubMed ID: 28729415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells.
    Huegel J; Dinh CT; Martinelli M; Bracho O; Rosario R; Hardin H; Estivill M; Griswold A; Gultekin S; Liu XZ; Fernandez-Valle C
    Oncotarget; 2022; 13():890-904. PubMed ID: 35875610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells.
    Bashour AM; Meng JJ; Ip W; MacCollin M; Ratner N
    Mol Cell Biol; 2002 Feb; 22(4):1150-7. PubMed ID: 11809806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microarray analysis of gene expression in vestibular schwannomas reveals SPP1/MET signaling pathway and androgen receptor deregulation.
    Torres-Martin M; Lassaletta L; San-Roman-Montero J; De Campos JM; Isla A; Gavilan J; Melendez B; Pinto GR; Burbano RR; Castresana JS; Rey JA
    Int J Oncol; 2013 Mar; 42(3):848-62. PubMed ID: 23354516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.
    Lee TX; Packer MD; Huang J; Akhmametyeva EM; Kulp SK; Chen CS; Giovannini M; Jacob A; Welling DB; Chang LS
    Eur J Cancer; 2009 Jun; 45(9):1709-20. PubMed ID: 19359162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism.
    Wong HK; Shimizu A; Kirkpatrick ND; Garkavtsev I; Chan AW; di Tomaso E; Klagsbrun M; Jain RK
    Neoplasia; 2012 Feb; 14(2):84-94. PubMed ID: 22431917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.